Loading...

CMIC HOLDINGS Co., Ltd.

2309.TJPX
HealthcareMedical - Diagnostics & Research
$2644.00
$12.00(0.46%)

CMIC HOLDINGS Co., Ltd. (2309.T) Stock Overview

Explore CMIC HOLDINGS Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for 2309.TStats details for 2309.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 2309.TAnalyst Recommendations details for 2309.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

CMIC HOLDINGS Co., Ltd. provides various services for the pharmaceutical industry in Japan. The company operates in five segments: Contract Research Organization, Contract Development and Manufacturing Organization, Contract Sales Organization, Healthcare, and Innovative Pharma Model. It offers clinical trial services, including clinical operations and trials, data management, clinical caretaker, medical writing, patient recruitment, pharmacovigilance, project management, audit and quality assurance, and statistical analysis; and clinical site network, CMC, drug development, health economics and outcome research, market entry/out-licensing, medical devices and in vitro diagnostic consulting, medical writing, national health insurance pricing, and product life cycle management consulting services. The company also provides development and manufacturing services, including commercial supply, contract development and manufacturing, investigational product manufacturing, packaging and labeling, release and stability tests, technology transfer, as well as formulation, process, and analytical development services; and laboratory services, such as bioanalysis and GLP analysis, biomarkers, CMC and GMP analysis, large molecule, oligonucleotides, small molecule, and toxicity, as well as safety pharmacology, in vitro and in vivo, and non-clinical studies. In addition, it offers patient and healthcare services, such as drug adherence support program, harmo, Helc+, prescription drug database, and selcheck services; and post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing, clinical research coordinating, clinical site administration, and site management services. CMIC HOLDINGS Co., Ltd. has a partnership with Science 37, Inc. to decentralize clinical trials and enhance the development of treatments. The company was incorporated in 1985 and is headquartered in Tokyo, Japan.

CEO

Dr. Kazuo Nakamura Ph.D.

Employees

4,684

Headquarters

Hamamatsucho Building, Tokyo

Founded

2004

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.